These controlled trials overall support the clinical utilization of PARP inhibitors as an element of therapeutic regimen for both ovarian and breast carcinoma to enhance progression-free survival; however, monotherapy appears to be supported for appropriate ovarian cancers only at this time. This evidence concerns the gene PARP1 and ovarian carcinoma.